Novelix Pharmaceuticals Limited (BOM:536565)
India · Delayed Price · Currency is INR 70.80
+3.37 (5.00%)
At close: Aug 4, 2026
Novelix Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,323 | 307.18 | 42.24 | 14.05 | 86.09 |
Other Revenue | 0.33 | 0.15 | 3.07 | 5.16 | 3.04 |
| 1,323 | 307.33 | 45.31 | 19.2 | 89.13 | |
Revenue Growth | 330.60% | 578.26% | 135.96% | -78.45% | -7.01% |
Cost of Revenue | 1,267 | 295.86 | 38.45 | 13.83 | 82.94 |
Gross Profit | 56.24 | 11.47 | 6.86 | 5.38 | 6.18 |
Selling, General & Admin | 7.18 | 0.89 | 1.88 | 3.56 | 5.79 |
Other Operating Expenses | 14 | 8.93 | 2.84 | 1.84 | 3.61 |
Operating Expenses | 22.2 | 10.21 | 6.48 | 5.96 | 11 |
Operating Income | 34.04 | 1.27 | 0.38 | -0.58 | -4.82 |
Interest Expense | - | - | - | - | -0.58 |
Interest & Investment Income | - | 0.01 | - | - | - |
Earnings From Equity Investments | - | - | - | - | 0.87 |
Other Non Operating Income (Expenses) | - | -0 | 0 | 0 | - |
EBT Excluding Unusual Items | 34.04 | 1.28 | 0.38 | -0.58 | -4.53 |
Gain (Loss) on Sale of Investments | - | - | - | - | -15.6 |
Gain (Loss) on Sale of Assets | - | -0.04 | -0.17 | - | -0.23 |
Pretax Income | 34.04 | 1.23 | 0.21 | -0.58 | -20.35 |
Income Tax Expense | 8.48 | 0.39 | 0.11 | 0.01 | -0.08 |
Earnings From Continuing Operations | 25.57 | 0.85 | 0.1 | -0.6 | -20.27 |
Net Income | 25.57 | 0.85 | 0.1 | -0.6 | -20.27 |
Net Income to Common | 25.57 | 0.85 | 0.1 | -0.6 | -20.27 |
Net Income Growth | 2924.85% | 711.76% | - | - | - |
Shares Outstanding (Basic) | 21 | 9 | 10 | 8 | 8 |
Shares Outstanding (Diluted) | 21 | 9 | 10 | 8 | 8 |
Shares Change | 124.99% | -9.80% | 28.54% | - | - |
EPS (Basic) | 1.21 | 0.09 | 0.01 | -0.07 | -2.50 |
EPS (Diluted) | 1.21 | 0.09 | 0.01 | -0.07 | -2.50 |
EPS Growth | 1244.44% | 800.00% | - | - | - |
Free Cash Flow | -256.45 | -137.91 | -3.43 | -24.1 | -2.12 |
Free Cash Flow Per Share | -12.14 | -14.69 | -0.33 | -2.98 | -0.26 |
Gross Margin | 4.25% | 3.73% | 15.14% | 27.99% | 6.94% |
Operating Margin | 2.57% | 0.41% | 0.85% | -3.04% | -5.41% |
Profit Margin | 1.93% | 0.27% | 0.23% | -3.12% | -22.74% |
Free Cash Flow Margin | -19.38% | -44.87% | -7.58% | -125.49% | -2.38% |
EBITDA | 35.05 | 1.65 | 0.77 | -0.02 | -4.02 |
EBITDA Margin | 2.65% | 0.53% | 1.69% | -0.12% | -4.51% |
D&A For EBITDA | 1.01 | 0.38 | 0.38 | 0.56 | 0.8 |
EBIT | 34.04 | 1.27 | 0.38 | -0.58 | -4.82 |
EBIT Margin | 2.57% | 0.41% | 0.85% | -3.04% | -5.41% |
Effective Tax Rate | 24.90% | 31.48% | 51.02% | - | - |
Revenue as Reported | 1,323 | 307.34 | 45.31 | 19.2 | 91.63 |
Advertising Expenses | - | 0.16 | 0.22 | 0.27 | 0.38 |